by Sabine Possmann | Dec 8, 2022 | Uncategorized
This year, the most important scientific price of the BAdW, endowed with 25.000 Euro, was awarded to Michael Hudecek, for his outstanding work on gen-modified CART-T cell therapy for cancer treatment. The Schelling price is awarded bi-annually, for outstanding...
by Sandra Annetzberger | Jul 25, 2022 | Uncategorized
An informative open access article was published on the current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. As one can tell from the article, the number of clincial trials for CAR-T multiple myeloma therapies is still rather low. While...
by Sandra Annetzberger | Jul 15, 2022 | Uncategorized
The 5th digital myeloma forum was a great success. On 9th July, the 5th edition of the Würzburg Myeloma Forum took place. With far more than 200 participants, mostly myeloma patients and their families as well as patient organisations, a large audience learned about...
by Sabine Possmann | Apr 4, 2022 | Uncategorized
VJHemOnc’s video series on CART cells interviewing HErmann Einsele During the EBMT-EHA 4th European CAR T-cell Meeting, VJHemOnc interviewed Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany on CAR-T therapy for multiple myeloma patients and...
by Sabine Possmann | Apr 1, 2022 | Uncategorized
VJHemOnc’s video series on CART cells interviewing Michael Hudecek During the EBMT-EHA 4th European CAR T-cell Meeting, VJHemOnc interviewed Michael Hudecek, MD, University of Würzburg, Würzburg, Germany on several exciting CAR-T topics. Watch the videos below,...
by Sandra Annetzberger | Feb 24, 2022 | Uncategorized
CARAMBA AT THE 4th European CART Cell Meeting As in the recent years, CARAMBA was well presented at the 4th European CART Cell Meeting which took place as a fully virtual event this year (10-12 February 2022). The meeting was jointly organised by EHA and EBMT...